Prostate Cancer Diagnostics



R-Action Distribution has exclusive worldwide distribution rights for the HistoScanning technology that it supports through its internal sales organisation and a distributor network.

Prostate HistoScanning™ is a unique Tissue Characterisation technology, specifically developed to detect, visualise and pinpoint the tissues under suspicion of harbouring cancer. It gives clinicians an immediate and clear view with accurate identification, location and volume of differentiated tissue in the prostate.

Prostate HistoScanning™ TT complements Tissue Characterisation with True Targeting functionality, enabling real-time guided biopsy in the same patient session.

Prostate HistoScanning™ and Prostate HistoScanning™ TT guides clinicians in making immediate, independent and informed decisions for each particular patient in their daily diagnostic routine while expanding the options for minimally-invasive treatments.

Example of guided biopsy

Target selection in the coronal plane and visualisation in 3D (CLI-101).

Image courtesy (CLI-101) of Dr. Johan G. Braeckman, Universitair Ziekenhuis Brussel (UZB), Belgium

Example of planning for brachytherapy

“Cognitive HistoScanning™-based intra-prostatic boost ‘dose painting’ using temporary brachytherapy is not easy to realise, yet–as our preliminary clinical trial data suggests–it is feasible.”

Courtesy of Prof. Dr. med. Vratislav Strnad, Strahlenklinik der Universitäts-Krebszentrum Erlangen (UCC) zur Friedrich-Alexander- Universität Erlangen-Nürnberg (FAU), Germany

Example of planning for nerve sparing surgery

Preoperative knowledge of the distribution and size of tumours might be useful for treatment planning of a nerve-sparing radical prostatectomy. A virtual cutting line was drawn on both sides of the prostate corresponding to areas where slices for Frozen Sections (FS) were taken. The FS is used to assess the posterior lateral margin of the excised prostate to determine whether there is any cancer at the margin of the resection line. If the margin is cancer-free then the primarily preserved neurovascular bundle can be left in situ without compromising the removal of all cancerous tissues. [12] It was shown that when no Prostate Histo- Scanning™ volume or a volume < 0.20mL was found at the left or right side of the prostate, the probability of a negative surgical margin at that side was 91%.

Image courtesy of PD Dr. med. Georg Salomon, Martini Klinik, Hamburg, Germany © 2013, BJUI. [12]